Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast–2034

The intravenous immunoglobulin (IVIG) market is witnessing steady and significant growth, supported by heightened awareness of immune-related disorders, a rising incidence of immunodeficiency conditions, and continued therapeutic innovation from leading pharmaceutical companies such as CSL Behring, Grifols, Octapharma, Kedrion, Takeda Pharmaceutical, Baxter International, ADMA Biologics, LFB Biotechnologies, Biotest AG, Shanghai RAAS Blood Products, China Biologics Products, BDI Pharma, and Intas Pharmaceuticals, among others.

DelveInsight’s “Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast–2034” report provides a comprehensive evaluation of the IVIG treatment landscape, including historical and projected epidemiological data and detailed market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The study thoroughly assesses existing treatment standards, pipeline candidates, individual therapy market shares, and IVIG market projections through 2034, offering valuable intelligence for stakeholders operating in this vital therapeutic segment.

According to DelveInsight’s findings, the IVIG market is positioned for long-term expansion due to a combination of factors, including deeper insights into disease pathophysiology, technological advancements in plasma sourcing and manufacturing processes, and a growing population of patients requiring immunoglobulin replacement therapy. The increasing prevalence of conditions such as primary immunodeficiency diseases, along with improvements in diagnostic infrastructure, continues to accelerate market growth.

Download the Intravenous Immunoglobulin Market report to explore the key factors driving the IVIG therapeutic landscape @ Intravenous Immunoglobulin Market Trends - https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Intravenous Immunoglobulin Epidemiology

The DelveInsight report delivers detailed epidemiological assessments covering both historical and current IVIG patient populations, along with forecasted trends across the seven major markets (7MM). The analysis highlights notable regional differences in patient distribution, with North America maintaining a dominant share of the overall market.

The epidemiology section examines the drivers behind current and projected trends through a combination of published studies and key opinion leader insights. It includes diagnosed patient pool estimates and clearly outlines the assumptions supporting these projections.

Patients eligible for IVIG therapy are categorized across multiple indications, including primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, Kawasaki disease, myasthenia gravis, and several autoimmune disorders. Among these, primary immunodeficiency diseases represent the largest revenue-generating segment, while Kawasaki disease is anticipated to demonstrate the most rapid growth over the forecast timeline.

Explore shifting patterns in IVIG patient pool projections @ Intravenous Immunoglobulin Epidemiology Analysis - https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Treatment Landscape and Pipeline Developments

The IVIG treatment ecosystem includes both established marketed therapies and promising late-stage pipeline candidates. The drug-focused segment of the report offers in-depth insights into approved IVIG products as well as Phase II and Phase III candidates, detailing clinical trial progress, mechanisms of action, regulatory milestones, and competitive positioning.

Recent advancements underscore the evolving nature of the IVIG space. For example, Evolve Biologics has completed a Phase III clinical study for its IVIG product, with regulatory filing anticipated in 2027. This marks a notable development in plasma-derived therapy, leveraging the company’s proprietary PlasmaCap EBA purification platform.

Broader pipeline analysis indicates continued exploration of innovative therapeutic strategies aimed at improving disease outcomes. Industry leaders—including CSL Behring, Grifols, Octapharma, Kedrion, Takeda Pharmaceutical, Baxter International, ADMA Biologics, LFB Biotechnologies, Biotest AG, Shanghai RAAS Blood Products, China Biologics Products, BDI Pharma, and Intas Pharmaceuticals—are actively investing in next-generation IVIG formulations designed to enhance efficacy, safety, and patient convenience.

1. Takeda Pharmaceutical Company Limited

Company & Country:
Takeda Pharmaceutical Company Limited — Japan (Headquarters in Tokyo/Osaka)

Product / Drug Candidate:

• Immune Globulin (liquid IVIG), including Kenketsu GLOVENIN-I 10% (IVIG)
• HYQVIA® (facilitated subcutaneous immunoglobulin / fSCIG) (IVIG + recombinant hyaluronidase)

Clinical Trial Phases & Registry IDs:

• Phase 3:
• • Liquid IVIG (improved Kenketsu GLOVENIN-I 10% IV formulation) — regulatory approval achieved in Japan (new formulation) with supportive Phase 3 data (JMA reviews).
• Phase 3 (SCIG / fSCIG):
• • HYQVIA® pivotal Phase 3 trials included NCT05150340 and NCT05513586 for agammaglobulinemia/hypogammaglobulinemia in Japan (registrations listed in press releases).
• Long-term Extension / Maintenance (Phase 3 / ongoing):
• • ADVANCE-CIDP 3 (Phase 3 extension in chronic inflammatory demyelinating polyneuropathy) leveraging HYQVIA (NCT02955355).

Mechanism of Action (MOA):

• IVIG / Immune Globulin: Polyclonal human IgG pooled from plasma donors that provides immune replacement (in immunodeficiency) and immunomodulatory effects via Fc receptor blockade, anti-idiotype interactions, and cytokine modulation.
• HYQVIA: Combines IVIG with recombinant human hyaluronidase (rHuPH20) to enhance dispersion and absorption subcutaneously — functionally similar immunoglobulin replacement with improved delivery characteristics.

Latest News / Updates:

• Approval of Kenketsu GLOVENIN-I 10% IVIG in Japan (Feb 2026), reflecting regulatory advancement of improved IVIG formulation.
• Multiple Phase 3 outcomes supporting safety and expanded clinical utility of HYQVIA in immunodeficiency and neuroinflammatory disorders.